Back to News
Market Impact: 0.35
Novartis Signs Deal With Abogen For MRNA Therapies
Source: Nasdaq
Healthcare & BiotechTechnology & InnovationM&A & Restructuring
Novartis entered a licensing and option agreement with China-based Abogen Biosciences to develop mRNA-encoded therapies. The deal includes an exclusive worldwide license to Abogen's lead asset, ABO2203, expanding Novartis's access to mRNA-based drug-development technology.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
moderately positive
Sentiment Score
0.45
Ticker Sentiment
NVS0.65
More News
- Big Pharma turns to China for new drugs as patent cliff drives multibillion-dollar deals
- Abogen signs $7.2 bln Novartis deal for mRNA autoimmune drug
- Mark Ruffalo says Paramount’s $111 billion Warner Bros. deal ‘Will stifle creativity, weaken free speech, and cost people their jobs’
- David Ellison says combined Paramount and Warner Bros. Discovery will be named Skydance
- Paramount and Warner Bros Discovery to become Skydance
- FAA says Boeing 737 Max software glitch not a flight-safety issue